Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of "Buy" from Analysts

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has received an average rating of "Buy" from the seven research firms that are presently covering the company, Marketbeat reports. Seven research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $9.83.

Several equities analysts have recently issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Sana Biotechnology in a research report on Friday, March 14th. They set a "buy" rating and a $7.00 price target for the company. Citizens Jmp upgraded shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price objective for the company in a research report on Tuesday, March 18th. JMP Securities reaffirmed a "market outperform" rating and set a $5.00 target price on shares of Sana Biotechnology in a research report on Tuesday. Finally, HC Wainwright restated a "buy" rating and issued a $11.00 price target on shares of Sana Biotechnology in a research report on Thursday, April 24th.

Sana Biotechnology Stock Down 2.4%

NASDAQ:SANA traded down $0.07 during mid-day trading on Friday, reaching $2.90. The stock had a trading volume of 3,520,273 shares, compared to its average volume of 3,681,262. Sana Biotechnology has a 1-year low of $1.26 and a 1-year high of $7.40. The stock's 50 day simple moving average is $2.12 and its two-hundred day simple moving average is $2.35.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02. Sell-side analysts predict that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

Several hedge funds have recently added to or reduced their stakes in SANA. Rhumbline Advisers raised its holdings in shares of Sana Biotechnology by 5.4% during the first quarter. Rhumbline Advisers now owns 182,134 shares of the company's stock worth $306,000 after acquiring an additional 9,359 shares during the period. SCS Capital Management LLC acquired a new stake in shares of Sana Biotechnology in the 1st quarter valued at about $137,000. Woodline Partners LP lifted its holdings in shares of Sana Biotechnology by 13.1% in the first quarter. Woodline Partners LP now owns 780,656 shares of the company's stock valued at $1,312,000 after purchasing an additional 90,515 shares in the last quarter. Clearline Capital LP bought a new stake in shares of Sana Biotechnology in the first quarter valued at about $690,000. Finally, AQR Capital Management LLC boosted its position in shares of Sana Biotechnology by 49.8% during the first quarter. AQR Capital Management LLC now owns 573,146 shares of the company's stock worth $963,000 after buying an additional 190,483 shares during the period. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.